For further appraising, the pathophysiological significance of our observations and the clinical potential of modulating Gβγ signaling for AD, we analyzed the effect of o-Aβ and gallein on APP/BACE1 interaction in human neurons. This evidence concerns the gene APP and Alzheimer disease.